From the tiny, delicate infant gut we have pioneered a new type of drug with the potential to eradicate asthma.
Essential gut microbes are necessary for establishing a healthy and resilient immune system. Infants who develop allergy and asthma in childhood harbor a distinct gut microbiome depleted of beneficial bacteria. Siolta aims to identify those infants at greater risk of disease by sampling their first bowel movement. The microbiome revealed there influences if that child will be among the ten percent of U.S. infants susceptible to asthma.
Infants who develop allergy and asthma in childhood harbor a distinct gut microbiome depleted of beneficial bacteria.It is the eradication and treatment of asthma that forms the initial focus of the Siolta mission. We are also using this platform to tackle additional allergic conditions before moving on to other inflammatory diseases.